Download as PDF JUNE 25, 2018 MINNEAPOLIS and WALTHAM, Mass., June 25, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today that it has reached agreement to acquire Exosome Diagnostics, Inc. for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones. The transaction is expected... Read more
Download as PDF JUNE 07, 2018 MINNEAPOLIS, June 7, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today it has reached agreement to acquire all of the stock of QT Holdings Corporation d/b/a Quad Technologies. The transaction is expected to close in early July and to be financed through available cash on hand. “We are... Read more
Download as PDF APRIL 24, 2018 MINNEAPOLIS, April 24, 2018 /PRNewswire/ — Bio-Techne Corporation announced today that it has hired Kim Kelderman as President, Diagnostics and Genomics, effective April 30, 2018. Mr. Kelderman will be based in California and will lead Bio-Techne’s diagnostics business; he will also drive and develop our strategic initiatives in genomics and genomics-based... Read more
New and updated assays increase application areas and improve performance MINNEAPOLIS, March 21, 2018 /PRNewswire/ — Bio-Techne has expanded the automation capabilities of its popular Advanced Cell Diagnostics (ACD)-branded RNAscope® in situ hybridization (ISH) technology with the launch of several new and updated assays. The developments increase both access to, and use of, RNAscope and improve overall robustness and ease-of-use.... Read more
MINNEAPOLIS, March 14, 2018 /PRNewswire/ — Bio-Techne has released MimEX™ GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface. 3-D cell culture and organoid models of the gastrointestinal epithelium are quickly being adopted for toxicology, drug discovery, and disease modeling. These more complex models provide a tremendous benefit over cell line- and primary... Read more
MINNEAPOLIS, Jan. 15, 2018 /PRNewswire/ — Bio-Techne now offers reagents and kits from Vector Laboratories, a leader in advanced labeling and detection solutions. Their innovative proprietary immunolabeling kits offer reliable, sensitive, and low background detection. In October 2017, Bio-Techne started distributing Vector Laboratories’ flagship products to complement its vast selection of Novus Biologicals® primary antibodies, including over 13,000 monoclonal-... Read more
MINNEAPOLIS, Jan. 2, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today that it has acquired all of the stock of Atlanta Biologicals, Inc. and its affiliated company, Scientific Ventures, Inc.. The transaction is financed through available cash on hand. Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne, commented, “Atlanta Biologicals is a great... Read more
Download as PDF NOVEMBER 20, 2017 MINNEAPOLIS, Nov. 20, 2017 /PRNewswire/ — Bio-Techne updated its Flow Cytometry Panel Builder tool in July 2017 to support the use of its vast selection of over 18,000 conjugated antibodies, across targets and colors. The Flow Cytometry Panel Builder, a version of the FluoroFinder tool, was first launched in... Read more
NOVEMBER 14, 2017 Melbourne-based melanoma researcher selected as the winner of ‘RNAscope ISH Get Hybridized’ giveaway, supporting cutting-edge research MINNEAPOLIS, Nov. 14, 2017 /PRNewswire/ — Advanced Cell Diagnostics (ACD), a Bio-Techne brand, has announced the winner of its ‘RNAscope ISH Get Hybridized’ giveaway, designed to recognize and support groundbreaking research with RNAscope® in situ hybridization (ISH) technology. The winner,... Read more
Download as PDF OCTOBER 26, 2017 MINNEAPOLIS, Oct. 26, 2017 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today the election of Dr. Alpna Seth and Dr. Joe Keegan to the company’s board of directors for a first term, effective today. Seth is Chief Operating Officer of Vir Biotechnology, Inc. and Keegan is an advisor to and director for several... Read more